SEC filingsOct 12, 2026 to Oct 19, 2026: insiders reported 840 purchases and sales across 212 companies.840 insider purchases and sales in 7 daysSee the filings →
HornScout

Company profile

KROS

Keros Therapeutics Inc.
NASDAQHealth Care

Latest close: 10.66 USD · Oct 16, 2026 · 1 year · split-adjusted

On the price, the facts of the public record■Insider buy□Insider sell●Results filed
With an account, also○dividends▲splits◌next earningswith an account

End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.

Latest on record

The most recent facts, as filed.

Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.

  1. Sep 29, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  2. Sep 28, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  3. Sep 8, 2026Material event · 8-KFiled by the company itself.Open the filing ↗

In numbers

What this profile holds, counted.

Closes · 1 year250
SEC filings on record50323 flagged findings
Reported transactions (Form 4)80since May 30, 2024 · and 27 other holdings
Corporate events (8-K)26since Oct 28, 2020

What the record says

Description, identity and filings, each with its source.

Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.

SEC record

SEC dossier

What this company has filed with the SEC, in plain language.

The 25 most recent filings (of 503)

Everything filed

Every SEC filing, newest first, with what it is. Below, each type with its own explanation.

  • Sep 29, 268-K ↗Current report · Communication to the market
  • Sep 28, 268-K ↗Current report · Communication to the market
  • Sep 10, 26S-3 ↗Securities offering
  • Sep 8, 268-K ↗Current report · Other events
  • Insider transaction · 5 Form 4 filingsshow all 5hide
  • Aug 18, 26Form 144 ↗Notice of proposed sale
  • Aug 13, 26Form 3 ↗Insider transaction
  • Aug 3, 268-K ↗Current report · Communication to the market
  • Aug 3, 2610-Q ↗Quarterly report
  • Aug 3, 268-K ↗Current report · Results
  • Jul 30, 268-K ↗Current report · Communication to the market
  • Jul 29, 26SCHEDULE 13G/A ↗Passive stake · BlackRock, Inc. · 8.4% · event on Jun 30, 26 · amendment
  • Jul 22, 268-K ↗Current report · A senior executive left or was appointed
  • Jul 17, 26SCHEDULE 13G ↗Passive stake · BlackRock Portfolio Management LLC · 5.7% · event on Jun 30, 26
  • Insider transaction · 2 Form 4 filingsshow all 2hide
  • Jul 6, 26Form 3 ↗Insider transaction
  • Jun 25, 268-K ↗Current report · A senior executive left or was appointed
  • Insider transaction · 2 Form 4 filingsshow all 2hide
  • Jun 11, 26Form 144 ↗Notice of proposed sale

503 filings on record, the oldest from Feb 13, 20.

Listing the 25 most recent filings of the 503 on record.

8-Ks, explained

Stress1Structure10Governance15
  • Governance3 senior executive changes2026show all 3hide
    • Jul 22, 26GovernanceA senior executive left or was appointed8-K 5.02 ↗
    • Jun 25, 26GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
    • Feb 26, 26GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Oct 15, 25StructureEntered a material agreement+5 more in the same filing8-K 1.01 ↗
  • Aug 6, 25GovernanceA senior executive left or was appointed+3 more in the same filing8-K 5.02 ↗
  • Jul 15, 25GovernanceA senior executive left or was appointed8-K 5.02 ↗
  • May 29, 25StressRestructuring plan with committed costs+2 more in the same filing8-K 2.05 ↗
  • Structure3 material agreements entered2024 – 2025show all 3hide
    • Apr 18, 25StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
    • Apr 10, 25StructureEntered a material agreement+4 more in the same filing8-K 1.01 ↗
    • Dec 3, 24StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Governance5 senior executive changes2023 – 2024show all 5hide
    • Oct 16, 24GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
    • Jun 17, 24GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
    • May 28, 24GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
    • Mar 5, 24GovernanceA senior executive left or was appointed8-K 5.02 ↗
    • Apr 19, 23GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
  • Jan 6, 23StructureEntered a material agreement8-K 1.01 ↗
  • Aug 4, 22GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Jan 31, 22GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Structure3 material agreements entered2021show all 3hide
    • Dec 13, 21StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
    • Sep 9, 21StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
    • Aug 5, 21StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Aug 2, 21GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗

2 older filings not shown

Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.

Ownership and control

Schedule 13D: stake and stated purpose

Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.

  • ADAR1 Capital Management, LLC13.3%Aug 21, 25SCHEDULE 13D/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum. · 4 earlier filings
  • Pontifax Management 4 GP (2015) Ltd.11.8%Apr 17, 25SCHEDULE 13D/A ↗6 co-filers on this document — the figure is the largest single stake, not their sum.

Schedule 13G: short-form filing

The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.

  • BlackRock, Inc.8.4%Jun 30, 26SCHEDULE 13G/A ↗1 earlier filing
  • TANG CAPITAL MANAGEMENT, LLC7.9%Oct 15, 25SCHEDULE 13G ↗6 co-filers on this document — the figure is the largest single stake, not their sum.
  • Nantahala Capital Management, LLC6.9%Mar 31, 26SCHEDULE 13G ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
  • Madison Avenue Partners, LP6.4%May 7, 25SCHEDULE 13G ↗6 co-filers on this document — the figure is the largest single stake, not their sum.
  • BlackRock Portfolio Management LLC5.7%Jun 30, 26SCHEDULE 13G ↗
show 5 more holdershide
  • The Vanguard Group5.0%Dec 31, 25SCHEDULE 13G/A ↗
  • D. E. Shaw & Co., L.P.3.9%Dec 31, 25SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • Madison Avenue International LP2.7%Dec 31, 25SCHEDULE 13G/A ↗6 co-filers on this document — the figure is the largest single stake, not their sum.
  • JPMORGAN CHASE & CO.0.2%Apr 30, 25SCHEDULE 13G/A ↗
  • ExodusPoint Capital Management, LP0.0%Dec 31, 25SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing

Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.

Sale intention announced

On Aug 18, Newton Charles W. filed notice of intent to sell up to $6K. It is filed under a scheduled plan (10b5-1), arranged in advance.

A notice is not a sale: it may not go ahead, may happen in part, or at a different price.

After the notice, they sold $6K on Aug 18, per their Form 4. That is 100% of the shares announced so far, and the window is still open.

SEC record

Insider transactions

Buys and sells reported by officers, directors and major shareholders on SEC Form 4.

Buys and sells

  • Aug 18, 26Sell$6KCharles W. Newton↗
  • Aug 18, 26Sell$37KLorena Raquel LernerChief Scientific Officer↗
  • Aug 18, 26Sell$46KEsther ChoChief Legal Officer↗
  • Aug 18, 26Sell$13KAnnita TaniniCorp. Controller & VP, Finance↗
  • Aug 17, 26Buy$10KJEAN JACQUES BIENAIME↗
  • Jul 15, 26Buy$11KJEAN JACQUES BIENAIME↗
  • Jun 15, 26Buy$10KJEAN JACQUES BIENAIME↗
  • Jun 11, 26Sell$6KCharles W. Newton↗
  • Jun 4, 26Sell$28KAlpna Seth↗
  • Jun 4, 26Sell$28KNima Farzan↗
  • Jun 4, 26Sell$28KJulius Knowles↗
  • May 15, 26Buy$11KJEAN JACQUES BIENAIME↗

There are 13 more transactions in this stretch.

Stock compensation, tax and giftsshow the 15 other transactionshide

Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.

  • Jul 1, 26Compensationamount n/aAnne Prener↗
  • Jun 3, 26Compensationamount n/aMARY ANN GRAY↗
  • Jun 3, 26Compensationamount n/aJEAN JACQUES BIENAIME↗
  • Jun 3, 26Compensationamount n/aJulius Knowles↗
  • Apr 2, 26Compensation$17KJasbir SeehraCHIEF EXECUTIVE OFFICER↗
  • Mar 9, 26Compensationamount n/aCharles W. Newton↗
  • Nov 21, 25Other$2.5MORBIMED ADVISORS LLC↗
  • Nov 21, 25Other$1.3MORBIMED ADVISORS LLC↗
  • Nov 21, 25Other$3.4MJulius Knowles↗
  • Nov 21, 25Other$2.3MJulius Knowles↗
  • Sep 3, 25Compensationamount n/aJasbir SeehraCHIEF EXECUTIVE OFFICER↗
  • Jun 20, 25Other$6KADAR1 Capital Management, LLC↗
  • Jun 20, 25Other$98KADAR1 Capital Management, LLC↗
  • Jun 20, 25Other$14KADAR1 Capital Management, LLC↗
  • Jun 4, 25Compensationamount n/aMARY ANN GRAY↗

The full record holds 69 transactions and goes back to Apr 13, 20.

Its sector and its market

Keros Therapeutics Inc. among Health Care companies

The profile shows what is on record. Context and Radar place the company among those of its sector and region.

With an account you also get

  • The four engines — growth, trend, risk and context — each with its word and its score.
  • The risk band and the sector phase.
  • The company's fundamentals and accounts.
  • Watchlist: your list of companies, with the «since you follow it» figure.

The research continues

The profile tells the story. The market sets the scene.

From Keros Therapeutics Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.

  1. Place it in its market

    Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.

    See how Context works →
  2. See what deserves a closer look

    Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.

    See how Radar works →
  3. Keep the why

    Follow Keros Therapeutics Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.

    See an example review →

Coverage

What sits behind this page.

Where each figure comes from and how far it reaches.

Prices
End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
Series quality
250 clean closes in the period.
SEC records
503 documents on file, from Feb 13, 2020 to Sep 29, 2026.
Company description
No description available.
This page
Generated on Oct 19, 2026; refreshed through the day.

Start at your own pace

Explore first. Go deeper with access.

Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.

Compare plans →
  • No account

    This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.

  • Pro

    What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.

  • Pro+

    Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.

Are the prices real time?

No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.

Which SEC documents appear here?

Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.

Why does a European company show no SEC records?

It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.

Before forming a view on a company,
read what is on record.

One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.

Access by invitation while the beta lasts. Not advice: the profile shows what is on record; it does not recommend.

Keros Therapeutics Inc. (KROS): stock price history, insider trades and SEC filings — HornScout